Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2009 1
2010 4
2011 5
2012 9
2013 8
2014 9
2015 17
2016 17
2017 9
2018 22
2019 18
2020 7
2021 22
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31262882

138 results

Results by year

Filters applied: . Clear all
Page 1
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J, Guan S, Zhao Y, Yu Y, Woodfield SE, Zhang H, Yang KL, Bieerkehazhi S, Qi L, Li X, Gu J, Xu X, Jin J, Muscal JA, Yang T, Xu GT, Yang J. Lu J, et al. Cancer Lett. 2017 Aug 1;400:61-68. doi: 10.1016/j.canlet.2017.04.022. Epub 2017 Apr 26. Cancer Lett. 2017. PMID: 28455243 Free PMC article.
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. Trigg RM, et al. Nat Commun. 2019 Nov 28;10(1):5428. doi: 10.1038/s41467-019-13315-x. Nat Commun. 2019. PMID: 31780656 Free PMC article.
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I. Shen J, et al. Cell Death Differ. 2018 Dec;25(12):2053-2070. doi: 10.1038/s41418-018-0080-0. Epub 2018 Mar 7. Cell Death Differ. 2018. PMID: 29515255 Free PMC article.
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, Van den Eynden J, Hallberg B, Palmer RH. Borenäs M, et al. EMBO J. 2021 Feb 1;40(3):e105784. doi: 10.15252/embj.2020105784. Epub 2021 Jan 7. EMBO J. 2021. PMID: 33411331 Free PMC article.
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S. Fukuda K, et al. Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8. Cancer Res. 2019. PMID: 30737231
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S. Chen Y, et al. Anticancer Drugs. 2018 Nov;29(10):935-943. doi: 10.1097/CAD.0000000000000667. Anticancer Drugs. 2018. PMID: 30074936
138 results